Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance
- PMID: 20692200
- PMCID: PMC2956795
- DOI: 10.1016/j.drup.2010.07.001
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance
Abstract
Although chemotherapy is an important therapeutic strategy for cancer treatment, it fails to eliminate all tumor cells due to intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Emerging evidence suggests an intricate role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT)-type cells in anticancer drug resistance. Recent studies also demonstrated that microRNAs (miRNAs) play critical roles in the regulation of drug resistance. Here we will discuss current knowledge regarding CSCs, EMT and the role of regulation by miRNAs in the context of drug resistance, tumor recurrence and metastasis. A better understanding of the molecular intricacies of drug-resistant cells will help to design novel therapeutic strategies by selective targeting of CSCs and EMT-phenotypic cells through alterations in the expression of specific miRNAs towards eradicating tumor recurrence and metastasis. A particular promising lead is the potential synergistic combination of natural compounds that affect critical miRNAs, such as curcumin or epigallocatechin-3-gallate (EGCG) with chemotherapeutic agents.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4. Adv Exp Med Biol. 2016. PMID: 26703799 Review.
-
Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.Expert Opin Ther Targets. 2015 Feb;19(2):285-97. doi: 10.1517/14728222.2014.975794. Epub 2015 Jan 7. Expert Opin Ther Targets. 2015. PMID: 25563894 Review.
-
MicroRNAs and cancer stem cells: the sword and the shield.Oncogene. 2014 Oct 16;33(42):4967-77. doi: 10.1038/onc.2013.492. Epub 2013 Nov 18. Oncogene. 2014. PMID: 24240682 Review.
-
Regulating miRNA by natural agents as a new strategy for cancer treatment.Curr Drug Targets. 2013 Sep;14(10):1167-74. doi: 10.2174/13894501113149990189. Curr Drug Targets. 2013. PMID: 23834152 Free PMC article. Review.
-
Pancreatic cancer stem cells: emerging target for designing novel therapy.Cancer Lett. 2013 Sep 10;338(1):94-100. doi: 10.1016/j.canlet.2012.03.018. Epub 2012 Mar 20. Cancer Lett. 2013. PMID: 22445908 Free PMC article. Review.
Cited by
-
Mature microRNA-binding protein QKI promotes microRNA-mediated gene silencing.RNA Biol. 2024 Jan;21(1):1-15. doi: 10.1080/15476286.2024.2314846. Epub 2024 Feb 19. RNA Biol. 2024. PMID: 38372062 Free PMC article.
-
Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review.Biomedicines. 2024 Jan 15;12(1):183. doi: 10.3390/biomedicines12010183. Biomedicines. 2024. PMID: 38255288 Free PMC article. Review.
-
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.J Exp Clin Cancer Res. 2023 Nov 28;42(1):325. doi: 10.1186/s13046-023-02903-x. J Exp Clin Cancer Res. 2023. PMID: 38017459 Free PMC article.
-
Role of Epithelial to Mesenchymal Transition in Colorectal Cancer.Int J Mol Sci. 2023 Oct 1;24(19):14815. doi: 10.3390/ijms241914815. Int J Mol Sci. 2023. PMID: 37834263 Free PMC article. Review.
-
Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms.Cell Prolif. 2023 Jun;56(6):e13423. doi: 10.1111/cpr.13423. Epub 2023 Feb 19. Cell Prolif. 2023. PMID: 36808651 Free PMC article. Review.
References
-
- Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008;15:739–752. - PubMed
-
- Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15:5060–5072. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA083695-09/CA/NCI NIH HHS/United States
- 1R01CA101870/CA/NCI NIH HHS/United States
- R01 CA131151/CA/NCI NIH HHS/United States
- 5R01CA131151/CA/NCI NIH HHS/United States
- R01 CA101870-05/CA/NCI NIH HHS/United States
- 5P20-CA101936/CA/NCI NIH HHS/United States
- 1R01CA132794/CA/NCI NIH HHS/United States
- P20 CA101936/CA/NCI NIH HHS/United States
- 5R01CA083695/CA/NCI NIH HHS/United States
- R01 CA101870/CA/NCI NIH HHS/United States
- R01 CA131151-04/CA/NCI NIH HHS/United States
- R01 CA132794-03/CA/NCI NIH HHS/United States
- R01 CA132794/CA/NCI NIH HHS/United States
- R01 CA083695/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources